Detection of small fragments of tumor DNA, known as circulating tumor DNA, in a patient's pre-surgery serum samples predicts early recurrence of hepatocellular carcinoma and may guide treatment, according to a study published in Cellular and Molecular Gastroenterology and Hepatology, the basic and translational science journal of the American Gastroenterological Association. Hepatocellular carcinoma—the most common type of liver cancer—is the third leading cause of cancer deaths worldwide.
↧